Current stock page

Stock Analysis

Praxis Precision Medicines, Inc. (PRAX) Stock Analysis

Praxis Precision Medicines, Inc. (PRAX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

PRAX Stock Analysis Summary

Praxis Precision Medicines, Inc. (PRAX) currently has an AIQ Score of 57/100, indicating a neutral setup. Quality is the strongest factor at 72/100. Risk is the weakest current factor at 47/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

PRAX at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$328.13
AIQ Score57/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Buy
Market Cap$9.57B
P/E Ratio (TTM)-25.6
Forward P/E—
EPS (Q3 FY2026)-$3.23
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.58
Volume352.89K
52-week range$160.11-$392.70
RSI 1461.44
50-Day SMA$289.90
200-Day SMA$314.58
Analyst Price Target$660.33
Next EarningsFeb 18, 2027
As of Nov 13, 2026 · Market close

PRAXPraxis Precision Medicines, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Strong Relative Position

NeutralEdge 9/10
$328.13+$3.37 (+1.04%)

Latest quote

  • Momentum
    48
  • Value
    —
  • Quality
    72
  • Risk resilience
    47
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

PRAX Stock Analysis Summary

Praxis Precision Medicines, Inc. (PRAX) currently has an AIQ Score of 57/100, indicating a neutral setup. Quality is the strongest factor at 72/100. Risk resilience is the weakest current factor at 47/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, PRAX has AIQ Score of 57/100 with Quality base of 72/100 and fading Risk resilience at 47/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (72/100) leads while Risk resilience (47/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 1.04% stock move · PRAX classified in Biotechnology.

Current Evidence

NeutralPRAX is in a neutral AIQ regime; Quality is the strongest visible factor at 72/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is PRAX Bullish or Bearish Right Now?

PRAX currently has a neutral overall setup. Quality is the strongest factor at 72/100, while Risk Resilience is weakest at 47/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Quality is supportive at 72/100.
  • - Price is +13.19% above its 50-day SMA.
  • - Analyst target implies +101.24% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (36 vs 4).
Bear Case
  • - Momentum is weak at 48/100.
  • - Risk Resilience is weak at 47/100.

Current Consensus

PRAX's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 6 neutral, and 4 sell votes. PRAX's 14-day RSI is 61.44, which places the stock in a constructive momentum range. PRAX's beta is 1.58, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in PRAX?

The largest recent change in PRAX is Quality moving down by 3.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
-1.0
Momentum
+1.0
Quality
-3.0
Risk
-2.0

What Would Change the PRAX Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

PRAX Decision Framework

Public evidence layers, setup checks, and risk context for Praxis Precision Medicines, Inc..

Praxis Precision Medicines, Inc. (PRAX) Stock Analysis

Praxis Precision Medicines, Inc. has an AIQ Score of 57/100 in a Neutral regime. Quality is strongest at 72/100. Beta is 1.58, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextPRAX is in a Neutral AIQ regime with score 57/100.
Signal ConflictThe primary conflict is that quality leads at 72/100 while risk lags at 47/100.
Factor EvidenceMomentum 48/100 · Quality 72/100 · Risk 47/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Quality is the strongest factor at 72/100.

TimingFail

Momentum is 48/100 and RSI (14) is 61.4.

Regime fitWait

PRAX is in a Neutral regime at 57/100.

Risk controlFail

Risk factor is 47/100 with beta 1.58 and annual volatility 75.11%.

ConflictWait

Current conflict: quality leads at 72/100 while risk lags at 47/100.

AIQ Score
57/100
Price
$328.13
Beta
1.58
RSI (14)
61.4

PRAX Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

PRAX Fundamentals

PRAX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$94.23M
Free cash flow
-$82.52M
View full PRAX fundamental analysis

PRAX Technical Analysis

PRAX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
61.44
Price vs SMA-50
+13.19%
View full PRAX technical analysis

PRAX Stock Catalysts

Track PRAX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 18, 2027
Analyst target
$660.33
News items
4
View PRAX earnings and stock catalysts

PRAX Dividend Analysis

PRAX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View PRAX dividend history and analysis

PRAX Financial Data

PRAX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$3.23
Periods
8
View PRAX financials

PRAX Risk Analysis

PRAX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.58
Risk score
47/100
1Y volatility
75.11%
View PRAX risk analysis

PRAX Stock News

PRAX stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 15, 2026
Sentiment
—
Read PRAX stock news

PRAX vs Biotechnology Peers

Current peer cohort: PRAX · PTGX · PVLA · QURE · RAPP. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
PRAX
Current stock
57/100—48/10047/1001.1375.11%Current
PTGX
Protagonist Therapeutics, Inc.
73/10072/10070/10070/1001.2440.11%PRAX vs PTGX
PVLA
Palvella Therapeutics, Inc.
70/100—84/10047/1001.1284.47%PRAX vs PVLA
QURE
uniQure N.V.
39/10038/10041/10031/1000.39132.25%PRAX vs QURE
RAPP
Rapport Therapeutics, Inc. Common Stock
43/10042/10033/10039/1000.3562.34%PRAX vs RAPP
Pairwise Compare links: PTGX · PVLA · QURE · RAPPPRAX vs PTGXPRAX vs PVLAPRAX vs QUREPRAX vs RAPPCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a PRAX stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for PRAX: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-25.6
As of Nov 13, 2026
Revenue growth
—
Gross margin
0.00%
Current debt / equity
0
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$94.23M
Quarter free cash flow
-$82.52M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bullish
RSI 14
61.44
MACD
13.06

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
47/100
Beta
1.58
Annual volatility
75.11%
Max drawdown
-38.13%

PRAX Stock FAQ

What is PRAX stock price today?

Praxis Precision Medicines, Inc.'s current stock price is $328.13. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is PRAX bullish or bearish right now?

PRAX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is PRAX's market cap?

PRAX's market cap is $9.57B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is PRAX's current P/E ratio?

PRAX's current P/E ratio is -25.6 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is PRAX's RSI?

PRAX's 14-day RSI is 61.44 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is PRAX above its 50-day and 200-day moving averages?

PRAX is 13.19% from its 50-day SMA and 4.31% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is PRAX's next earnings date?

PRAX's next earnings date is currently listed as Feb 18, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does PRAX pay a dividend?

PRAX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.